• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Augmentation of Serotonin Reuptake Inhibitors in Refractory Obsessive-Compulsive Disorder Using Adjunctive Olanzapine: A Placebo-Controlled Trial.
【24h】

Augmentation of Serotonin Reuptake Inhibitors in Refractory Obsessive-Compulsive Disorder Using Adjunctive Olanzapine: A Placebo-Controlled Trial.

机译：使用辅助性奥氮平在难治性强迫症中增强5-羟色胺再摄取抑制剂：安慰剂对照试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The purpose of this study was to explore the efficacy of adding an atypical antipsychotic, olanzapine, to a serotonin reuptake inhibitor (SRI) in treatment-refractory obsessivecompulsive disorder (OCD). METHOD: Twenty-six patients aged between 18 and 65 (mean = 41.2, SD = 11.9) years meeting DSM-IV criteria for OCD, who had not responded to SRIs, were treated for 6 weeks in a double-blind, placebo-controlled augmentation study with either olanzapine (up to 20 mg/day) or placebo. Severity of illness was assessed biweekly by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Analysis of covariance with baseline Y-BOCS score included as a covariate was used to compare improvement in Y-BOCS scores in the 2 groups. Response was defined as a 25% or greater improvement in Y-BOCS score. Data were collected between April 2001 and May 2003. RESULTS: Outcome was assessed for all patients using the last observation carried forward. Subjects in the olanzapine group had a mean decrease of 4.2 (SD = 7.9)in Y-BOCS score compared with a mean increase in score of 0.54 (SD = 1.31) for subjects in the placebo group (F = 4.85, df = 2,23; p =.04). Six (46%) of 13 subjects in the olanzapine group showed a 25% or greater improvement in Y-BOCS score compared with none in the placebo group. The final mean dose of olanzapine was 11.2 (SD = 6.5) mg/day. Medication was well tolerated. Only 2 (15%) of 13 subjects who received olanzapine discontinued because of side effects: sedation (N = 1) or weight gain (N = 1). CONCLUSION: These results provide preliminary evidence that adding olanzapine to SRIs is potentially efficacious and well tolerated in the short-term treatment of patients with refractory OCD. Controlled studies with larger sample sizes are necessary to more definitively address this treatment strategy.
机译：背景：这项研究的目的是探讨在5-羟色胺再摄取抑制剂（SRI）中加入非典型抗精神病药奥氮平对难治性强迫症（OCD）的疗效。方法：对不符合SRI的DSM-IV标准的18岁至65岁（平均= 41.2，SD = 11.9）的26岁患者（对SRI没有反应），在双盲，安慰剂对照下治疗6周奥氮平（最高20毫克/天）或安慰剂进行的增强研究。通过耶鲁-布朗强迫症量表（Y-BOCS）每两周评估一次疾病的严重程度。协方差分析与基线Y-BOCS得分一起作为协变量，用于比较两组的Y-BOCS得分的改善。响应定义为Y-BOCS得分提高25％或更高。在2001年4月至2003年5月之间收集了数据。结果：使用最近进行的观察评估所有患者的结果。奥氮平组受试者的Y-BOCS得分平均下降4.2（SD = 7.9），而安慰剂组受试者的平均得分提高0.54（SD = 1.31）（F = 4.85，df = 2， 23; p = .04）。与安慰剂组相比，奥氮平组的13名受试者中有6名（46％）的Y-BOCS得分提高了25％或更高。奥氮平的最终平均剂量为11.2（SD = 6.5）mg / day。药物耐受性良好。在接受奥氮平治疗的13名受试者中，只有2名（15％）因以下副作用而停药：镇静（N = 1）或体重增加（N = 1）。结论：这些结果提供了初步的证据，表明在奥沙平中添加奥氮平在难治性强迫症患者的短期治疗中可能有效且耐受性良好。为了更明确地解决该治疗策略，必须进行具有较大样本量的对照研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号